Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

Early Phase 1
3(75.0%)
Phase 1
1(25.0%)
4Total
Early Phase 1(3)
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT05008146Early Phase 1Recruiting

Imaging CRF X NOP Interactions in CUD

Role: lead

NCT05011760Early Phase 1Recruiting

[C-11]NPA PET-amphetamine in Cocaine Use Disorders

Role: lead

NCT03448016Early Phase 1Completed

[C-11]NOP-1A and Alcohol Use Disorder

Role: lead

NCT01904487Phase 1Completed

Characterization of [11C]Flumazenil to Image GABA Transmission in Healthy Adult Subjects and Subjects With Alcohol Dependence

Role: lead

All 4 trials loaded